Tiziana Life Sciences PLC (TLSA) shares are trading at $2.67in premarket trading today, up 12.18%. Last trading session, Tiziana stock fell -7.03% to $2.38. TLSA stock traded 0.37 million shares, which is below the average daily trading volume of 0.43 million shares over the last 50 days.
TLSA stock has gained 3.03% in the last five days, but has gained 4.39% over the last month. Following a move of treating Covid-19 in-home, TLSA stock is rising.
What was the inspiration behind TLSA’s solution?
A UK biotech company, Tiziana is dedicated to discovering and developing new molecules for treating cancer and immune diseases. Milciclib (a CDK inhibitor) is one of several drugs TLSA is developing, including Foralumab for Multiple Sclerosis, Crohn’s Disease, and COVID-19. Formulab is a fully human second generation anti-CD3 monoclonal antibody developed exclusively by TLSA is currently being studied in clinical trials.
To achieve further clinical development of foralumab as a nasal spray, Tiziana has submitted a grant to the UK COVID Therapeutics Advisory Panel (UK-CTAP), announced TLSA today.
- As an innovative “Take Home” therapy for non-hospitalized COVID-19 patients, TLSA’s Formulab is a fully human anti-CD3 monoclonal antibody.
- The TLSA’s move followed a UK government request for proposals to study home-based therapies that would reduce hospitalizations.
- It is imperative that Foralumab be further developed in patients with Covid-19 with nasal administration.
TLSA’s other initiatives include:
A separate clinical trial is also being prepared by Tiziana (TLSA) in Brazil involving hospitalized patients with COVID-19. A key objective of this study by TSLA is to determine whether patients hospitalized with severe inflammation might benefit from nasally administered Foralumab.
In addition to the COVID-19 variants identified in South Africa, Brazil, the UK, and India, nasal administration with Foralumab has the possibility of being useful for the treatment of other COVID-19 variants.
